Martha A. Nance, MD
Research Investigator & Medical Director, Struthers Parkinson’s Center
About

Title: Researcher

Medical Director, Struthers Parkinson’s Center

Academic appointment: Adjunct Professor, Department of Neurology, University of Minnesota

Joined the Institute: 1997

Education and training: MD, Medical College of Virginia; Residency, Neurology, University of Minnesota; Fellowship, clinical genetics, University of Minnesota

Overview/research interests: Clinical trials in Parkinson’s disease and Huntington’s disease and related disorders and identification/description of novel neurogenetic disorders.

Current research activities and funding:

  • MICT-PD (Park Nicollet)
  • Cynapsus trial (medication for wearing off)
  • PDGENE (Parkinson’s Foundation)
Affiliation
positions
  • Research Investigator, Neuroscience Research Centers
    • Publications While At HealthPartners
    selected publications
    Journal Article
  • Providing genetic testing and genetic counseling for Parkinson's disease to the community. 
    Genetics in Medicine. 2023
  • Tools for communicating risk for Parkinson's disease. 
    NPJ Parkinson's disease. 2022
  • Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. 
    Genetics in Medicine. 2020
  • Quality improvement in Parkinson's disease: a successful program to enhance timely administration of Levodopa in the hospital. 
    Journal of Parkinson's Disease. 2020
  • Assessment of the performance of a modified motor scale as applied to juvenile onset Huntington's disease
    2019
  • End-of-life measures in Huntington disease: HDQLIFE meaning and purpose, concern with death and dying, and end of life planning. 
    Journal of Neurology. 2019
  • Use and perceived effectiveness of complementary therapies in Parkinson's disease. 
    Parkinsonism & Related Disorders. 2019
  • A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning. 
    Journal of Neurology. 2018
  • Agreement between clinician-rated versus patient-reported outcomes in Huntington disease. 
    Journal of Neurology. 2018
  • Relationships among apathy, health-related quality of life, and function in Huntington's disease. 
    Journal of Neuropsychiatry and Clinical Neurosciences. 2018
  • A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. 
    Neurology. 2017
  • A survey-based study identifies common but unrecognized symptoms in a large series of juvenile Huntington's disease. 
    Neurodegenerative Disease Management. 2017
  • Genetics of Huntington disease. 
    Handbook of Clinical Neurology. 2017
  • National randomized controlled trial of virtual house calls for Parkinson disease. 
    Neurology. 2017
  • Reliability and validity of the HD-PRO-TriadTM, a health-related quality of life measure designed to assess the symptom triad of Huntington's disease
    2017
  • Clinical-genetic associations in the Prospective Huntington at Risk Observational Study (PHAROS): implications for clinical trials. 
    JAMA neurology. 2016
  • HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). 
    Quality of Life Research. 2016
  • HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, speech difficulties, and swallowing difficulties. 
    Quality of Life Research. 2016
  • Health care delivery practices in Huntington's disease specialty clinics: an international survey
    2016
  • MECR mutations cause childhood-onset dystonia and optic atrophy, a mitochondrial fatty acid synthesis disorder. 
    American Journal of Human Genetics. 2016
  • National randomized controlled trial of virtual house calls for people with Parkinson's disease: Interest and barriers. 
    Telemedicine Journal and e-Health. 2016
  • New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system). 
    Quality of Life Research. 2016
  • The impact of oculomotor functioning on neuropsychological performance in Huntington disease. 
    Journal of Clinical and Experimental Neuropsychology. 2016
  • Huntington disease
    2015
  • Managing residents with Parkinson's disease in long-term care
    2015
  • Motor onset and diagnosis in Huntington disease using the diagnostic confidence level. 
    Journal of Neurology. 2015
  • Multivariate clustering of progression profiles reveals different depression patterns in prodromal Huntington disease. 
    Neuropsychology. 2015
  • Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. 
    Lancet Neurology. 2015
  • Sex differences in clinical features of early, treated Parkinson's disease. 
    PloS One. 2015
  • The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study. 
    Movement Disorders. 2015
  • Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD Study. 
    Frontiers in Aging Neuroscience. 2014
  • Clinical, demographic, and pharmacologic features of nursing home residents with Huntington's disease. 
    Journal of the American Medical Directors Association. 2014
  • Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. 
    JAMA neurology. 2014
  • Experience, knowledge, and opinions about childhood genetic testing in Batten disease. 
    Molecular Genetics and Metabolism. 2014
  • Treatment of myoclonus-dystonia syndrome with tetrabenazine. 
    Parkinsonism & Related Disorders. 2014
  • Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. 
    Neurogenetics. 2013
  • Managing juvenile Huntington's disease. 
    Neurodegenerative Disease Management. 2013
  • CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. 
    Neurology. 2012
  • Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. 
    Neurology. 2012
  • Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. 
    American Journal of Human Genetics. 2012
  • Population stratification may bias analysis of PGC-1alpha as a modifier of age at Huntington disease motor onset. 
    Human Genetics. 2012
  • TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. 
    Biochemical and Biophysical Research Communications. 2012
  • Genetic testing in clinical practice. 
    Continuum (Minneapolis, Minn.). 2011
  • Impulsive behavior and associated clinical variables in Parkinson's disease. 
    Psychosomatics. 2011
  • Neuropsychological profile of parkin mutation carriers with and without Parkinson disease: the CORE-PD Study. 
    Journal of the International Neuropsychological Society. 2011
  • Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. 
    Neurology. 2011
  • Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. 
    Brain. 2011
  • Challenges assessing clinical endpoints in early Huntington disease. 
    Movement Disorders. 2010
  • Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. 
    Archives of Neurology. 2010
  • Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. 
    Archives of Neurology. 2010
  • Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. 
    Journal of Clinical and Experimental Neuropsychology. 2010
  • Striatal and white matter predictors of estimated diagnosis for Huntington disease. 
    Brain Research Bulletin. 2010
  • Genomewide association study for susceptibility genes contributing to familial Parkinson disease. 
    Human Genetics. 2009
  • A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. 
    Parkinsonism & Related Disorders. 2008
  • Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. 
    Neurology. 2008
  • Replication of association between ELAVL4 and Parkinson disease: the GenePD study. 
    Human Genetics. 2008
  • The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. 
    BMC Medicine. 2008
  • Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. 
    Brain. 2007
  • Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. 
    Movement Disorders. 2007
  • Verbal episodic memory declines prior to diagnosis in Huntington's disease. 
    Neuropsychologia. 2007
  • A new locus for dominant hereditary spastic paraplegia maps to chromosome 2p12. 
    Neurogenetics. 2006
  • Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. 
    BMC Medical Genetics. 2006
  • Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31. 
    American Journal of Human Genetics. 2006
  • Antigliadin antibodies in Huntington's disease. 
    Neurology. 2004
  • Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations. 
    Neurogenetics. 2004
  • A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. 
    American Journal of Human Genetics. 2003
  • Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. 
    Archives of Neurology. 2003
  • Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. 
    Neurology. 2003
  • Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. 
    Human Molecular Genetics. 2003
  • Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. 
    American Journal of Medical Genetics. Part A. 2003
  • Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. 
    American Journal of Human Genetics. 2003
  • Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. 
    Annals of Neurology. 2003
  • Predictors of nursing home placement in Huntington disease. 
    Neurology. 2003
  • Seeking clarity through the genetic lens: a work in progress. 
    Annals of Neurology. 2003
    • Editorial Article
  • Intronic pentanucleotide expansion in the replication factor 1 gene (RFC1) is a major cause of adult-onset ataxia [editorial]. 
    Neurology. Genetics.  6. 2020
  • Attention training improves attention and gait in Parkinson disease: a pilot study [editorial]. 
    Parkinsonism & Related Disorders.  60. 2019
  • Defining pediatric Huntington disease: time to abandon the term Juvenile Huntington Disease [editorial]?. 
    Movement Disorders.  34. 2019
  • Family history in juvenile Huntington disease: do the signs point to "yes" or "very doubtful" [editorial]?. 
    Neurology.  80. 2013
    • Review
  • Genetic counseling and testing for Huntington's disease: a historical review [review]. 
    American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics. 2017
  • Incomplete nonsense-mediated decay facilitates detection of a multi-exonic deletion mutation in SGCE [review]. 
    Clinical Genetics. 2013
  • Therapy in Huntington's disease: where are we [review]?. 
    Current Neurology and Neuroscience Reports. 2012
    • Book
  • Caregiver guide for mid to late stage Huntington's disease: for long-term care facilities and in-home care agencies
    2015
    • Contact
    full name
  • Martha A. Nance, MD
    • located in facility
    Quick Info
     
    Collaboration
    More Info